食管癌免疫治疗的现状与展望

Current status and prospects of immunotherapy in esophageal cancer

食管癌的治疗是临床难点。近年来免疫检查点抑制剂将肿瘤免疫治疗带入了一个新的时代。在预测疗效的生物标志物中，程序性死亡受体．配体1、肿瘤突变负荷和微卫星不稳定性等生物标志物在免疫检查点抑制剂疗效预测上非常有前景。各种免疫检查点抑制剂层出不穷，免疫联合治疗在食管癌的临床试验中显示出巨大的应用潜力。

The treatment of esophageal cancer is difficult in clinic. Recently, the development of immune checkpoint inhibitors has brought the immunotherapies to a new age. In predicting the curative effect of biomarkers, programmed cell death-ligand 1, tumor mutation burden and microsatellite instability could promi- singly predict the effect of the immune checkpoint inhibitors. Various immune checkpoint inhibitors are emerging and the combination of immunotherapy have shown a great applied potential in a series of clinical trials of esophageal cancer.